Involvement of tumor necrosis factor receptor type II in FoxP3 stability and as a marker of Treg cells specifically expanded by anti-tumor necrosis factor treatments in rheumatoid arthritis
Arthritis & Rheumatology Mar 08, 2020
Santinon F, Batignes M, Mebrek ML, et al. - In order to examine the involvement of Treg cells expressing tumor necrosis factor receptor type II (TNFRII) in exerting control of inflammation in experimental models and in the response to anti-TNF treatments in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA), researchers explored the role of TNFRII in Treg cells applying a multilevel translational approach. This study assessed Treg cell stability by examining the methylation status of the FoxP3 locus using bisulfite sequencing. The evolution of the TNFRII+ Treg cell population before and after targeted treatment was monitored in individuals with RA and those with SpA. The outcomes indicated that TNFRII expression distinguishes a subset of Treg cells that are marked by stable expression of FoxP3 via gene hypomethylation, and adoptive transfer of TNFRII-expressing Treg cells ameliorates inflammation in experimental models. It was demonstrated that expansion and activation of TNFRII+ Treg cells may be one of the mechanisms by which anti-TNF agents control inflammation in RA, but not in SpA.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries